Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated After Definitive Chemoradiotherapy

Overview

Journal Cancer Res Treat

Specialty Oncology

Date 2014 Jan 24

PMID 24454000

Citations 16

Authors

Dae-Eun Kim

Uh-Jin Kim

Won-Young Choi

Mi-Young Kim

Seung-Hun Kim

Min-Jee Kim

Hyun-Jeong Shim

Jun-Eul Hwang

Woo-Kyun Bae

Ik-Joo Chung

Taek-Keun Nam

Kook-Joo Na

Sang-Hee Cho

Affiliations

Soon will be listed here.

Abstract

Purpose: Locally advanced esophageal cancers are generally treated with neoadjuvant chemoradiotherapy, followed by surgery in operable candidates. However, even if the patients were diagnosed as operable disease, surgery could not be performed on patients with poor condition or other comorbidity. In this case, definitive chemoradiotherapy (dCRT) is the other option for localized esophageal cancer. Therefore, the purpose of this study was to evaluate the efficacy and clinical prognostic factors for dCRT in locally advanced esophageal cancer.

Materials And Methods: We conducted a review of patients who received dCRT for locally advanced squamous esophageal cancer from 2004 to 2010, focusing on stages III and IVa. All patients received at least two cycles of platinum-based chemotherapy during radiation, and all tumor burdens were included in the radiation field. The treatment results were analyzed for patterns of failure and prognostic factors associated with survival.

Results: In total, 63 patients were enrolled in this study. The overall response rate was 84.1%. Relief from dysphagia after dCRT was achieved in 48 patients. The most frequent failure was local recurrence. The median overall survival (OS) was 23.0 months, and the 2-year survival rate was 45.4%. Similar results were observed for elderly study patients. Significant prognostic factors for OS were duration of smoking, high grade of dysphagia (score of 3 or 4), and shorter duration of progression-free and dysphagia-free survival. Maintenance chemotherapy after dCRT did not influence OS. However, "good risk" patients receiving maintenance chemotherapy showed better OS than those who did not receive maintenance chemotherapy (30.4 months vs. 12.0 months, p=0.002).

Conclusion: dCRT has a major role in improving survival and palliation of dysphagia in inoperable advanced esophageal cancer, even in elderly patients. Maintenance chemotherapy after dCRT may be effective in prolonging survival in "good risk" patients.

Citing Articles

Maintenance chemotherapy for esophageal squamous cell carcinoma after standard concurrent chemoradiotherapy: a national propensity score matching cohort study.

Tseng S, Chen W, Jao A, Chen M, Shia B, Wu S Am J Cancer Res. 2024; 14(5):2300-2312.

PMID: 38859861 PMC: 11162678. DOI: 10.62347/BCKH8310.

Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.

Xiang G, Xu C, Chai G, Lyu B, Li Z, Wang B Radiat Oncol. 2023; 18(1):114.

PMID: 37430276 PMC: 10334638. DOI: 10.1186/s13014-023-02265-w.

Irradiation-induced exosomal HMGB1 to confer radioresistance via the PI3K/AKT/FOXO3A signaling pathway in ESCC.

Du X, Zhang X, Dong J, Zou N, Guo D, Yao W J Transl Med. 2022; 20(1):507.

PMID: 36335371 PMC: 9636677. DOI: 10.1186/s12967-022-03720-0.

Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.

Liu A, Wang Y, Wang X, Zhu L, Nie Y, Li M Radiat Oncol. 2021; 16(1):195.

PMID: 34600574 PMC: 8487511. DOI: 10.1186/s13014-021-01921-3.

Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.

Wang J, Xiao L, Wang S, Pang Q, Wang J Front Oncol. 2021; 11:665231.

PMID: 34589418 PMC: 8473880. DOI: 10.3389/fonc.2021.665231.

References

Crosby T, Brewster A, Borley A, Perschky L, Kehagioglou P, COURT J . Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer. 2004; 90(1):70-5. PMC: 2395332. DOI: 10.1038/sj.bjc.6601461. View

OGILVIE A, Dronfield M, Ferguson R, Atkinson M . Palliative intubation of oesophagogastric neoplasms at fibreoptic endoscopy. Gut. 1982; 23(12):1060-7. PMC: 1419858. DOI: 10.1136/gut.23.12.1060. View

Yamashita H, Nakagawa K, Tago M, Nakamura N, Shiraishi K, Mafune K . The intergroup/RTOG 85-01 concurrent chemoradiation regimen for Japanese esophageal cancer. Hepatogastroenterology. 2006; 53(72):863-8. View

Stahl M, Wilke H, Fink U, Stuschke M, Walz M, Siewert J . Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol. 1996; 14(3):829-37. DOI: 10.1200/JCO.1996.14.3.829. View

Hurmuzlu M, Monge O, Smaaland R, Viste A . High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: toxicity and outcome. Dis Esophagus. 2009; 23(3):244-52. DOI: 10.1111/j.1442-2050.2009.00999.x. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Enzinger P, Mayer R . Esophageal cancer. N Engl J Med. 2003; 349(23):2241-52. DOI: 10.1056/NEJMra035010. View

Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle J, VAITKEVICIUS V . Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997; 15(1):277-84. DOI: 10.1200/JCO.1997.15.1.277. View

Lin C, Chang S, Wei Y, Chou T, Wu Y, Lin H . Prognostic variables in thoracic esophageal squamous cell carcinoma. Ann Thorac Surg. 2009; 87(4):1056-65. DOI: 10.1016/j.athoracsur.2008.11.051. View

10.

Cooper J, Guo M, Herskovic A, Macdonald J, Martenson Jr J, Al-Sarraf M . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17):1623-7. DOI: 10.1001/jama.281.17.1623. View

11.

Liao Z, Zhang Z, Jin J, Ajani J, Swisher S, Stevens C . Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys. 2004; 60(5):1484-93. DOI: 10.1016/j.ijrobp.2004.05.056. View

12.

Jung K, Park S, Kong H, Won Y, Lee J, Seo H . Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012; 44(1):11-24. PMC: 3322196. DOI: 10.4143/crt.2012.44.1.11. View

13.

Shim H, Cho S, Hwang J, Bae W, Song S, Cho S . Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer. Am J Clin Oncol. 2010; 33(6):624-8. DOI: 10.1097/COC.0b013e3181bead92. View

14.

STEIGER Z, Franklin R, Wilson R, Leichman L, Seydel H, Loh J . Eradication and palliation of squamous cell carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy. J Thorac Cardiovasc Surg. 1981; 82(5):713-9. View

15.

Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H . Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer. 2008; 99(10):1586-92. PMC: 2584940. DOI: 10.1038/sj.bjc.6604749. View

16.

Tomblyn M, Goldman B, Thomas Jr C, Benedetti J, Lenz H, Mehta V . Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). J Thorac Oncol. 2012; 7(5):906-12. PMC: 3382003. DOI: 10.1097/JTO.0b013e31824c7bed. View

17.

Di Fiore F, Lecleire S, Rigal O, Galais M, Ben Soussan E, David I . Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006; 12(26):4185-90. PMC: 4087370. DOI: 10.3748/wjg.v12.i26.4185. View

18.

Morita M, Nakanoko T, Fujinaka Y, Kubo N, Yamashita N, Yoshinaga K . In-hospital mortality after a surgical resection for esophageal cancer: analyses of the associated factors and historical changes. Ann Surg Oncol. 2011; 18(6):1757-65. DOI: 10.1245/s10434-010-1502-5. View

19.

Muijs C, Beukema J, Mul V, Langendijk J . In Response to: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 75(5):1623. DOI: 10.1016/j.ijrobp.2009.07.1738. View

20.

Sun D . Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys. 1989; 16(2):329-34. View